Raland Therapeutics is a finalist in the $5M 43North competition. Click here to read the article
CHARLESTON, SC – Efferent Labs®, a vanguard in biotechnological innovation, today announced a
(BUFFALO, NY) Apr. 1, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in
(BUFFALO, NY) Feb. 15, 2022—Efferent Labs, Inc., a preclinical-stage biodevice company focused on in
Efferent Labs offers a live, cellular data acquisition platform that will radically alter the landscape of pre-clinical research in animals.
Efferent Labs® offers a live, cellular data acquisition platform that will radically alter the landscape of pre-clinical research in animals.
Sign up for email alerts of Press Releases and Efferent Labs’ breaking news
